Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome

Chapman, R W; Stanghellini, Vincenzo; Geraint, Mike; Halphen, M.

doi:10.1038/ajg.2013.197

Cited by 142 publications

(90 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study results were in concordance to the previously published literature where osmotic and bulk laxatives were used in relieving the constipation-related symptoms in patients with IBS-C and FC. 35,36 However, the point to highlight here is that, only 36.6% patients of FC and 50.9% patients of IBS-C were on laxative therapy. Moreover, about 1/5 th patients of FC were using home remedies for the same.…”

Section: Discussionmentioning

confidence: 87%

Prevalence of functional constipation and constipation-predominant irritable bowel syndrome in Indian patients with constipation

Rooprai

Bhat

Sainani³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Evaluate prevalence of functional constipation (FC) and irritable bowel syndrome-constipation (IBS-C) in Indian constipated patients and assess their demographic/socio-economic/clinical characteristics.Methods: Patients (≥18 years) who visited their general physician with symptoms of constipation (Rome III criteria for FC or IBS-C as per physician assessment) and willing to participate were enrolled in this prospective, clinical-epidemiological study. Demographic, socioeconomic status, lifestyle and dietary habits, comorbid conditions, treatment history, concomitant medications, stool form (Bristol stool form scale), severity of constipation (constipation scoring system [CSS]), constipation-related symptoms (patient assessment of constipation symptoms [PAC-SYM]) and quality of life (patient assessment of constipation-quality of life questionnaire [PAC-QoL]) were recorded.Results: Out of 925 constipated patients, 75.6% were diagnosed with FC against 24.4% with IBS-C (P < 0.0001). Patients of both subtypes had high average scores of PAC-SYM (FC: 27.1 ± 6; IBS-C: 30.1 ± 4.9) and CSS (FC: 8.4 ± 3.1; IBS-C: 11.2 ± 3), leading to high PAC-QoL score (FC: 38.1 ± 16.8; IBS-C: 42.2 ± 13.6). Hypertension (16%) and diabetes (10%) in patients with FC while acid peptic disorders (21.7%) amongst IBS-C patients were the most common comorbid conditions observed. Laxatives were the most common medication used; osmotic (32.6% versus 40.7%) and bulk laxatives (22.8% versus 37.4%) were the commonest laxatives. However, about 1/5th patients of FC were using home remedies.Conclusions: There was a higher prevalence of FC over IBS-C in Indian constipated patients; both subtypes had high frequency and severity of constipation-related symptoms and poor QoL.

show abstract

Section: Discussionmentioning

confidence: 87%

Prevalence of functional constipation and constipation-predominant irritable bowel syndrome in Indian patients with constipation

Rooprai

Bhat

Sainani³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…A recent placebo controlled RCT in IBS-C found PEG to be effective in increasing bowel frequency (between group difference 1.56 spontaneous bowel movements [SBMs]/week, P < 0.0001) but not severity of abdominal pain (between group difference -0.04, P > 0.05). 30 A similar study in adolescents demonstrated an improvement in stool frequency with PEG but no impact on pain intensity. 31 …”

Section: Current Therapies For Constipationpredominant Irritable Bowementioning

confidence: 84%

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation

Eswaran¹,

Guentner²,

Chey³

2014

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Irritable bowel syndrome with constipation and chronic functional constipation are common digestive disorders that negatively impact quality of life and account for billions of dollars in health care costs. Related to the heterogeneity of pathogenesis that underlie these disorders and the failure of symptoms to reliably predict underlying pathophysiology, traditional therapies provide relief to only a subset of affected individuals. The evidence surrounding new and emerging pharmacologic treatments, which include both luminally and systemically acting drugs, is discussed here. These include agents such as lubiprostone, bile acid modulations, guanylate cyclase-C receptor agonists, serotonin receptor modulators and herbal therapies.

show abstract

“…The first one found no superiority over placebo (88). The second trial found benefits in terms of defecatory frequency but not of abdominal pain and distension (89).…”

Section: Efficacymentioning

confidence: 99%

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Mearin¹,

Ciriza²,

Mínguez³

et al. 2016

Rev Esp Enferm Dig

103

151

View full text Add to dashboard Cite

In this Clinical Practice Guideline we discuss the diagnostic and therapeutic approach of adult patients with constipation and abdominal complaints at the confluence of the irritable bowel syndrome spectrum and functional constipation. Both conditions are included among the functional bowel disorders, and have a significant personal, healthcare, and social impact, affecting the quality of life of the patients who suffer from them. The first one is the irritable bowel syndrome subtype, where constipation represents the predominant complaint, in association with recurrent abdominal pain, bloating, and abdominal distension. Constipation is characterized by difficulties with or low frequency of bowel movements, often accompanied by straining during defecation or a feeling of incomplete evacuation. Most cases have no underlying medical cause, and are therefore considered as a functional bowel disorder. There are many clinical and pathophysiological similarities between both disorders, and both respond similarly to commonly used drugs, their primary difference being the presence or absence of pain, albeit not in an "all or nothing" manner. Severity depends not only upon bowel symptom intensity but also upon other biopsychosocial factors (association of gastrointestinal and extraintestinal symptoms, grade of involvement, and perception and behavior variants). Functional bowel disorders are diagnosed using the Rome criteria. This Clinical Practice Guideline has been made consistent with the Rome IV criteria, which were published late in May 2016, and discuss alarm criteria, diagnostic tests, and referral criteria between Primary Care and gastroenterology settings. Furthermore, all the available treatment options (exercise, fluid ingestion, diet with soluble fiber-rich foods, fiber supplementation, other dietary components, osmotic or stimulating laxatives, probiotics, antibiotics, spasmolytics, peppermint essence, prucalopride, linaclotide, lubiprostone, biofeedback, antidepressants, psychological therapy, acupuncture, enemas, sacral root neurostimulation, surgery) are discussed, and practical recommendations are made regarding each of them.

show abstract

Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome

Cited by 142 publications

References 24 publications

Prevalence of functional constipation and constipation-predominant irritable bowel syndrome in Indian patients with constipation

Prevalence of functional constipation and constipation-predominant irritable bowel syndrome in Indian patients with constipation

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation

Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult

Contact Info

Product

Resources

About